Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Infectious disease

HIV/AIDS

Not applicable

In vitro studies suggest inducing an IgG3 response against HIV antigens could help create protective immunity against infection. In a clinical trial, Sanofi's ALVAC HIV vaccine and a bivalent clade B/E recombinant gp120 immunogen induced an antigen-specific IgG3 response and partial protective immunity, whereas another vaccination regimen that induced a weaker IgG3 response did not result in protective immunity. Next steps could include developing a vaccination strategy that induces a persistent IgG3 response.
ALVAC HIV is in Phase III testing.

SciBX 7(17); doi:10.1038/scibx.2014.496
Published online May 1, 2014

Patent and licensing status unavailable

Yates, N.L. et al. Sci. Transl. Med.; published online March 19, 2014;
doi:10.1126/scitranslmed.3007730
Contact: Georgia D. Tomaras, Duke University, Durham, N.C.
e-mail:

gdt@duke.edu